Explore 3 Stock Ideas & Industry Insights Download Free Report

INmune Bio Inc

Company price
1.03 USD -0.01 ( 0.96%)
Last update at 2026-11-18T21:00:00Z
VOLUME
751879
Market Cap
62.72M

Momentum Score

…

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.92
Low
1.07
High
52 Week Price Range
1.09
Low
2.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

INmune Bio is a clinical-stage biotechnology company developing therapies that modulate the innate immune system to address cancers and neurodegenerative disorders. Long-term growth may benefit from advancement of clinical-stage programs, validation of its immune‑modulating approach, possible collaborations or licensing, and continuing demand for novel immunotherapies, which could make the company attractive to investors seeking exposure to early-stage, mechanism-driven drug development.

The most important investment risks are clinical and regulatory failure, ongoing capital requirements that could dilute shareholders, and intense competition in oncology and neurology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.04
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-74.82%
Net Debt
-23.72M
ROCE
-191.91%
Diluted EPS TTM
-0.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -45.93M -42.08M -30.01M -27.30M -30.34M
Net income -45.93M -42.08M -30.01M -28.65M -30.34M
Selling general administrative 10.26M 9.48M 9.62M 9.26M 8.79M
Selling and marketing expenses - - 0.16M - -
Gross profit 0.05M 0.01M 0.15M 0.37M 0.18M
Reconciled depreciation 0.08M 0.00M - - -
Ebit -45.93M -42.08M -30.01M -25.95M -29.15M
Ebitda -45.85M -41.53M -0.27M -25.95M -29.15M
Depreciation and amortization 0.08M 0.55M 29.74M -1.35M -1.19M
Non operating income net other - - - - -1.19M
Operating income -30.87M -42.63M -29.74M -25.95M -29.15M
Other operating expenses 30.92M 42.65M 29.90M 26.32M 29.33M
Interest expense - - - 1.35M 1.19M
Income tax expense - - -29.74M 1.35M 1.19M
Total revenue 0.05M 0.01M 0.15M 0.37M 0.18M
Total operating expenses 30.92M 42.65M 29.90M 26.32M 29.33M
Total other income expense net -15.06M 0.55M -0.27M -1.35M -1.19M
Net income from continuing ops -45.93M -42.08M -27.43M -25.95M -30.34M
Net income applicable to common shares - - - -27.30M -30.34M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 32.35M 39.56M 57.00M 81.80M 99.94M
Intangible assets - 16.51M 16.51M 16.51M 16.51M
Other current assets 0.59M 0.33M 1.65M 4.03M 7.80M
Total liab 8.83M 7.46M 18.86M 21.69M 19.72M
Total stockholder equity 23.52M 32.10M 38.14M 60.10M 80.22M
Other current liab 0.03M 0.52M 8.43M 0.62M 0.47M
Common stock 0.03M 0.02M 0.82M 0.02M 0.02M
Capital stock 0.03M 0.02M 0.82M 0.02M 0.02M
Retained earnings -209.04M -163.10M -121.02M -91.01M -63.72M
Other liab - - - 0.55M 0.20M
Other assets - - 0.00M 0.10M 0.10M
Cash 24.75M 20.92M 35.85M 52.15M 74.81M
Total current liabilities 8.42M 7.22M 18.46M 10.92M 4.36M
Current deferred revenue - - 0.49M - -
Net debt -23.72M -20.54M -25.41M -36.84M -59.58M
Short term debt 0.62M 0.14M 10.04M 5.09M 0.07M
Short long term debt - - 9.92M 5.00M -
Short long term debt total 1.03M 0.38M 10.44M 15.31M 15.23M
Other stockholder equity 233.27M 195.75M 158.34M 151.80M 143.92M
Property plant equipment - - - 0.51M 0.73M
Total current assets 29.89M 22.66M 39.94M 64.67M 82.61M
Net tangible assets - - - 43.59M 63.71M
Net receivables 4.54M 1.41M 2.44M 8.46M 5.50M
Long term debt - - - 9.70M 14.46M
Inventory - - - 0.03M -5.50M
Accounts payable 7.77M 6.56M 7.94M 5.21M 3.81M
Accumulated other comprehensive income -0.74M -0.57M -0.80M -0.70M 0.00M
Common stock total equity - - - 0.02M 0.02M
Retained earnings total equity - - - -91.01M -63.72M
Non currrent assets other 1.55M 0.08M 0.13M 0.10M 0.10M
Non current assets total 2.46M 16.90M 17.06M 17.12M 17.34M
Capital lease obligations 1.03M 0.38M 0.52M 0.61M 0.78M
Long term debt total - - - 9.70M 14.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 0.00M -15.00M
Change to liabilities - - - 1.75M 2.46M
Total cashflows from investing activities -1.04M - - - -15.00M
Net borrowings 0.00M -10.00M -5.00M - 14.95M
Total cash from financing activities 27.61M 18.21M -4.22M 0.73M 96.36M
Change to operating activities - - - -4.27M -5.35M
Net income -45.93M -42.08M -30.01M -27.30M -30.34M
Change in cash 3.83M -14.93M -16.30M -22.66M 52.84M
Begin period cash flow 20.92M 35.85M 52.15M 74.81M 21.97M
End period cash flow 24.75M 20.92M 35.85M 52.15M 74.81M
Total cash from operating activities -22.58M -33.36M -11.98M -22.69M -28.50M
Issuance of capital stock 27.54M 27.79M 0.78M 0.70M 80.25M
Depreciation 0.08M 0.00M 0.22M 0.24M 0.13M
Other cashflows from investing activities -1.04M - - - -15.00M
Change to account receivables -3.13M 1.03M 6.02M - -
Sale purchase of stock - - - 0.03M 81.41M
Other cashflows from financing activities 27.61M 0.42M 0.78M 0.03M 16.10M
Change to netincome - - - 7.15M 4.80M
Capital expenditures 1.04M 0.00M 0.00M 0.00M 15.00M
Change receivables - - - 0.23M -
Cash flows other operating - - - -4.76M -5.55M
Exchange rate changes - - - - -0.01M
Cash and cash equivalents changes - - - -21.96M 52.84M
Change in working capital -2.53M 1.04M 10.44M -2.86M -3.09M
Stock based compensation 9.91M 7.61M 7.37M 7.15M 4.80M
Other non cash items 15.89M 0.08M 0.22M 0.33M 0.13M
Free cash flow -23.62M -33.36M -11.98M -22.69M -43.50M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INMB
INmune Bio Inc
-0.01
0.96%
1.03 - - 760.34 3.19 286.00 -5.31
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

INmune Bio Inc

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

225 NE Mizner Blvd., Boca Raton, FL, United States, 33432

561 710 0512

21

Name Title Year Born
Dr. Raymond Joseph Tesi M.D. Co-Founder, Pres, CEO, Chief Medical Officer & Chairman 1956
Mr. David J. Moss M.B.A. CFO, Treasurer & Sec. 1970
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer 1963
Mr. Joshua S. Schoonover Esq. Assoc. Gen. Counsel NA
Dr. Christopher J. Barnum Head of Neuroscience NA
Dr. Raymond Joseph Tesi M.D. Co-Founder, President, CEO, Chief Medical Officer & Chairman 1956
Mr. David J. Moss M.B.A. CFO, Treasurer & Secretary 1970
Mr. Joshua S. Schoonover Esq. General Counsel NA
Mr. David J. Moss M.B.A. President, CEO, Treasurer, Secretary & Director 1970
Mr. Cory Randall Ellspermann Interim Chief Financial Officer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…